Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators (SERMS).

Adolfo Diez-Perez1

  • 1Department of Internal Medicine, Autonomous University of Barcelona, Hospital del Mar-URFOA-IMIM, Barcelona, Spain. adiez@imas.imim.es

Arquivos Brasileiros De Endocrinologia E Metabologia
|November 23, 2006
PubMed
Summary

Selective Estrogen Receptor Modulators (SERMs) offer targeted benefits for bone density and menopausal symptom relief. These compounds provide an alternative to hormone therapy, mitigating risks like breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

A meta-analysis of smoking and fracture risk to update the FRAX® tool.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Body mass index and subsequent fracture risk: a meta-analysis to update FRAX.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Estrogen receptors, specifically estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), have been known for decades.
  • ERalpha and ERbeta exhibit distinct tissue expression patterns, influencing various physiological processes.
  • Estrogen therapy provides benefits for bone density and menopausal symptoms but carries risks, including increased breast cancer incidence.

Purpose of the Study:

  • To explore the role and therapeutic potential of Selective Estrogen Receptor Modulators (SERMs).
  • To compare the efficacy and safety profiles of SERMs against traditional estrogen therapy.
  • To highlight the advancements in understanding hormone-receptor interactions through SERM development.

Main Methods:

  • Review of existing literature on estrogen receptors and SERMs.

Related Experiment Videos

  • Analysis of the chemical structures and properties of various SERM classes.
  • Evaluation of the effects of SERMs on bone turnover, bone density, and potential side effects.

    • Main Results:

    • Over seventy SERM molecules across five chemical groups have been identified.
    • SERMs activate estrogen receptors, reduce bone turnover, and improve bone density.
    • SERMs offer a targeted efficacy profile, potentially avoiding some side effects associated with hormone therapy.

    Conclusions:

    • SERMs represent a significant advancement in modulating estrogen receptor activity.
    • Their clinical utility is primarily recognized for their effects on breast cancer and bone health.
    • SERMs provide a valuable therapeutic option with a potentially improved benefit/risk profile compared to conventional hormone therapy.